As with most neurological disorders, making an accurate diagnosis of Parkinson’s disease (PD) is often complicated. The standard diagnosis of PD is clinical, meaning there’s no test, such as a blood test, that can give a conclusive result. Instead, certain physical symptoms need to be present to qualify a diagnosis of PD.
On Monday 2nd October, the Financial Conduct Authority (FCA) published its ‘Review of terminal illness benefits within life insurance protection products’. Full details of the background to the review, who it applies to and how the work was conducted can be found at the link below:
It was the end of an era at the close of Q1 2024. SCOR Cardiology CMO, Dr Jeremy Sayer has decided to hang up his stethoscope and retire. Dr Sayer has been SCOR’s Cardiology CMO for over 20 years and we have been so very grateful for all the advice and wisdom he has shared with us over the years.
Parkinson's disease, a complex and debilitating neurological disorder, has become increasingly prevalent in recent years, significantly impacting the lives of individuals and their families. As a progressive condition with no known cure, it brings a range of motor and non-motor symptoms that can lead to severe disability. The financial burden associated with Parkinson's disease, particularly for those diagnosed at younger ages, highlights the need for some form of insurance, whether it be Critical Illness (CI) or Income Protection (IP).
Personalised diagnostics is an area of science that is based on the idea that a person’s own clinical, genetic, genomic and environmental information can identify patient-specific diseases and target individual medical treatments to maximise response and help reduce adverse effects.
Over the last year, there has been a constant stream of media articles relating to the development of weight loss drugs, with research claiming that significant improvements in weight can be achieved, and an ever-growing list of new drugs being developed and approved for use.
These drugs are known as glucagon-like peptide-1 (GLP-1) receptor agonists medications and are a class of drugs that have for some time been available for managing type 2 diabetes (T2DM) and more recently have emerged as an effective treatment option for weight loss.
All insurers aspire to pay every claim that lands on their desk. The claims process is the “moment of truth”, and our aim is to help vulnerable people; those with critical illnesses and the recently bereaved with the financial support they need, when that need it at its greatest. As an industry, we support thousands of customers, and the figures recently released by the ABI are testament to that.
In 2017 I wrote an article on how the use of modulators could potentially lead to a shift in how we approach Cystic Fibrosis (CF) from an underwriting perspective. At the time modulators had been around for approximately 5 years and were offering promising outcomes for the select CF sufferers who were fortunate enough to be eligible for the drugs. I wrote about the future of CF being bright and how the insurance industry may need to refine its underwriting approach to the condition, which, was falling into the ‘uninsurable’ category for the most part.
As SCOR celebrates the 10th anniversary of our publication SCORacle, it’s fitting that we report on a subject that appeared in our very first edition back in November 2014 yet remains as ever very topical, e-cigarettes (e cigs) /vaping.
Over the last 10 years, we have been true to our word, keeping you, our audience informed of developments and news on e-cigarettes /vaping usage as well as looking at potential risks as we all learned more on published research.
